Literature DB >> 3621132

Distinguishing features of primary hyperparathyroidism in patients with breast cancer.

D M Axelrod, R S Bockman, G Y Wong, M P Osborne, D W Kinne, M F Brennan.   

Abstract

Thirty-five women with breast cancer and primary hyperparathyroidism (1 degree HPT) were admitted to Memorial Hospital during a 25-year period. The incidence of primary hyperparathyroidism in the breast cancer patients was similar to the incidence in the total patient population at Memorial Sloan-Kettering Cancer Center (0.15% and 0.14%, respectively). The patients with 1 degree HPT disease had clinical findings which distinguished them from those patients with cancer-related hypercalcemia. Eighty percent of the breast cancer patients with primary hyperparathyroidism had earlier stage disease (Stage 0, Stage 1, Stage 2); whereas 97% of the patients with breast cancer and hypercalcemia (not due to 1 degree HPT) had advanced disease. There appeared to be a trend towards improved survival in the breast cancer patients with primary hyperparathyroidism when compared to patients of similar stage of disease who did not have parathyroid disease.

Entities:  

Mesh:

Year:  1987        PMID: 3621132     DOI: 10.1002/1097-0142(19871001)60:7<1620::aid-cncr2820600733>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Primary hyperparathyroidism and metastatic carcinoma within parathyroid gland.

Authors:  L Venkatraman; A Kalangutkar; C F Russell
Journal:  J Clin Pathol       Date:  2007-09       Impact factor: 3.411

2.  Increased prevalence of primary hyperparathyroidism in treated breast cancer.

Authors:  P Fierabracci; A Pinchera; P Miccoli; P F Conte; E Vignali; M Zaccagnini; C Marcocci; C Giani
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

3.  Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.

Authors:  Tariq Chukir; Yi Liu; Katherine Hoffman; John P Bilezikian; Azeez Farooki
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

4.  PRIMARY HYPERPARATHYROIDISM AND SERUM CALCIUM IN BREAST CANCER PATIENTS EVALUATED FOR LOW BONE MASS - A SINGLE CENTER EXPERIENCE.

Authors:  Marija Punda; Petra Petranović Ovčariček; Anita Tabain; Klaas Pieter Koopmans; Gabriela Alfier; Tomislav Jukić; Ana Fröbe
Journal:  Acta Clin Croat       Date:  2021-12       Impact factor: 0.932

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.